Recent developments highlight FDA approval of the Allurion Gastric Balloon System, regulatory challenges including NYSE delisting proceedings, and financial performance issues such as reported losses and liquidity concerns.

• Allurion Technologies received FDA PMA approval for its Allurion Gastric Balloon System in February 2026, marking a key regulatory milestone [N3].
• The company was notified by the NYSE in March 2026 of proceedings to delist its common stock due to failure to maintain minimum market capitalization, and trading was suspended on the NYSE; the company is appealing this decision [S1].
• Following the NYSE suspension, Allurion’s common stock is trading on the OTCID Market, with intentions to list on a higher-tier OTC market [S1].
• The company reported a net loss of $28.76 million and negative EPS of $3.81 for the fiscal year ended December 31, 2025, with liquidity ratios indicating financial constraints [S1].
• Capital structure adjustments included warrant inducement transactions in early 2026 to lower exercise prices and issue new warrants, aiming to improve financial flexibility [S1].
• Industry outlooks and analyst commentary have highlighted Allurion among medical product stocks facing a challenging industry environment [N4][N5][N6].
• The company reported a significant revenue drop of 71% in Q2 2025 and a loss for the same period, reflecting operational challenges [N7][N8].

The FDA PMA approval of the Allurion Gastric Balloon System represents a significant regulatory milestone that validates the company’s core product and may facilitate market adoption. The company’s efforts to restructure its capital through warrant inducements and amendments could provide improved financial flexibility. Continued regulatory compliance and successful commercialization of its products could enhance its competitive position in the weight management medical device market.

The company reported a substantial net loss and exhibits liquidity challenges with a current ratio well below 1, indicating potential difficulties in meeting short-term obligations. The delisting from the NYSE due to insufficient market capitalization may reduce stock liquidity and investor interest, complicating capital raising efforts. The company operates in a highly competitive and regulated industry, facing risks related to maintaining regulatory approvals, market acceptance, and evolving economic conditions. These factors may constrain operational and financial performance.

Allurion’s moat is primarily based on its proprietary medical device technology, specifically the Allurion Gastric Balloon System, which has received FDA PMA approval, indicating regulatory validation and potential market exclusivity. The company’s focus on non-surgical weight management solutions positions it in a specialized niche within the medical device industry. However, the company faces competitive pressures and regulatory risks common to medical device companies, and its financial constraints may limit its ability to invest in growth and defend its market position.

• Regulatory Risk: The company’s business depends on maintaining FDA approvals and satisfying regulatory requirements for its products, including the Allurion Gastric Balloon System.
• Liquidity and Financial Risk: Low current and cash ratios indicate liquidity constraints, which may impact the company’s ability to fund operations and meet obligations.
• Market Listing Risk: The company received a delisting notice from the NYSE due to non-compliance with market capitalization standards and is currently trading on the OTCID Market, which may reduce liquidity and investor access.
• Competitive and Market Risk: The company operates in a highly competitive medical device industry with pricing pressures and evolving market dynamics.
• Operational Risk: The company’s ability to successfully commercialize its products and manage clinical trials and studies affects its business prospects.

• Allurion Technologies, Inc. is a company listed under ticker ALUR.
• The company is an emerging growth company as defined by SEC rules.
• As of December 31, 2025, the company had cash and cash equivalents of $5.41 million and current assets of $12.79 million.
• As of December 31, 2025, current liabilities were $38.45 million, resulting in a current ratio of 0.33 and a cash ratio of 0.14, indicating liquidity constraints.
• The company reported a net loss of $28.76 million for the fiscal year ended December 31, 2025, with basic and diluted EPS of -$3.81 per share.
• The company received FDA PMA approval for its Allurion Gastric Balloon System, a key product, as reported in February 2026.
• The company faced a delisting notice from the NYSE in March 2026 due to non-compliance with minimum market capitalization requirements and is appealing this determination.
• The company has engaged in warrant inducement transactions and amendments to improve capital structure, including lowering exercise prices and issuing new warrants.
• Recent news highlights include FDA approval, regulatory challenges, and industry outlooks mentioning Allurion among medical product stocks in a challenging industry.
• The company’s stock is currently trading on the OTCID Market following suspension from the NYSE pending appeal.
• The company’s business operations and reporting requirements continue despite the delisting notice.
• The company’s risk factors include regulatory approval maintenance, market competition, economic conditions, and the impact of delisting on liquidity and financing ability.